Skip to main content
. 2015 Mar 2;4(6):e1008824. doi: 10.1080/2162402X.2015.1008824

Figure 5.

Figure 5.

Tumor cell expression of PD-L1 and PD-L2 after incubation with activated NK supernatant or IFNγ. (A) Expression of PD-L1 in a representative example of AML cells treated with NK supernatant (left panel) or IFNγ (right panel) and with the addition of JAK inhibitor. (B) Expression of PD-L1 in hematopoietic tumor cell lines and primary tumor cells and expression of PD-L2 in U937 and primary AML cells. Surface antigen expression (MFI) is compared in cells incubated with medium alone, NK supernatant or IFNγ with or without JAK inhibitor. (C) Expression of PD-L1 in K562 or K562-STAT1-KO cells treated with NK supernatant (left panel) or IFNγ (right panel). (D) Expression of PD-L1 in 3 STAT1-KO or sh-CTRL cell lines. PD-L1 expression (MFI) is compared in cells incubated with medium alone, NK-supernatant or IFNγ.